Manufacturers: App pharmaceuticals llc, Bedford laboratories div ben venue laboratories inc +17 more
Carboplatin is a alkylating agent used to treat advanced ovarian cancer.
Carboplatin is a alkylating agent used to treat advanced ovarian cancer.
Carboplatin predominantly acts by attaching alkyl groups to the nucleotides, leading to the formation of monoadducts, and DNA fragmenting when repair enzymes attempt to correct the error. 2% of carboplatin's activity comes from DNA cross-linking from a base on one strand to a base on another, preventing DNA strands from separating for synthesis or transcription. Finally, carboplatin can induce a number of different mutations.
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
20 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
Showing the 100 most relevant patent families.
